Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

By afschroeder • April 30, 2026

Shachar EK, Silverstein J, Kwan L, Salani R, Karlan BY, Chase DM. Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers? Gynecol Oncol. 2026 Apr 28;209:26-32. doi: 10.1016/j.ygyno.2026.04.011. Epub ahead of print. PMID: 42054783.

Tags: age, antibody drug conjugates, Ethnicity, gynecologic cancer, Hematology/Oncology, Publications, Race, Underrepresented minorities

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]

Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies

Berkowitz MJ, Arzoo KK. Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies. Cureus. 2026 Oct 6;18(10):e117545. doi: 10.7759/cureus.117545. PMID: 42992212; PMCID:[...]

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC

Altan M, Navani V, Kim HR, Sun L, Paz-Ares L, Chmielewska I, Lin CC, Cuppens K, Mountzios I, Peled N, Cappuzzo F, Wang B, Zhou[...]